close
MENU
Tech & Innovation
5 mins to read

Pictor takes a step closer to heavy-hitting US investors

Auckland company’s immunodiagnostics platform has wide application, but is honed on Covid-19 antibody detection and ruminant disease.

Pictor has created a saliva test that can identify a host of Covid-19 anitbodies.

Dita De Boni Mon, 05 Dec 2022

Auckland-based human and animal immunodiagnostics firm Pictor has once again tapped one of its better-known shareholders to lead a new investment round that it hopes will place it squarely under the nose of some of America’s largest investment firms.

Former Morrison & Co CEO Marko Bogoievski, who

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
NZ Aviation News

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Aviation News - Monthly

NZ$14.95 / monthly

Already have an account? Login
Contact the Writer: dita@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Pictor takes a step closer to heavy-hitting US investors
Tech & Innovation,
96910
true